PEACE-2 finds adding cabazitaxel to ADT plus radiotherapy fails to improve survival in high-risk localized prostate cancer, while increasing severe toxicities and deaths.

At 7.3 years’ median follow-up, cabazitaxel failed to improve clinical PFS (62.8% vs 67.2%), metastasis-free survival, or overall survival versus androgen deprivation therapy plus radiotherapy.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced the commercial launch of ELEVIDYS (delandistrogene moxeparvovec) in Japan by Chugai ...

Ten percent complete response and rapid, durable antitumor activity reported with RYBREVANT FASPRO; results surpass current standards of care RARITAN, N.J., Feb. 19 ...

Johnson & Johnson today announced new results from the Phase 1b/2 OrigAMI-4 study showing that first-line treatment with investigational subcutaneous amivantamab and hyaluronidase-lpuj in combination ...

Patients with IIMs who were AMA-M2 positive vs negative had a greater risk for cardiac involvement, though overall survival was similar between groups.

New designation is based on data showing rapid and durable responses in a heavily pretreated patient population and expands the promise of RYBREVANT ...

Monthly dosing reduces treatment visits while maintaining established safety and efficacy1,2 Builds on RYBREVANT FASPRO FDA approval to deliver the simplest and fastest ...

Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved a new, simplified monthly dosing schedule* for RYBREVANT FASPROtm (amivantamab and hyaluronidase-lpuj). When ...

Bitcoin broke through $90K resistance on January 3 after ETFs pulled in $471M on January 2. BTC now trades around $92K-$94K. A break above $95K could trigger a gamma squeeze toward $100K. Elevated ...